Pair Name | Dihydroartemisinin, Osimertinib | ||
Phytochemical Name | Dihydroartemisinin (PubChem CID: 3000518 ) | ||
Anticancer drug Name | Osimertinib (PubChem CID: 71496458 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Dihydroartemisinin, Osimertinib | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->ROS generation | |||
Gene Regulation | Down-regulation | Expression | HMOX1 | hsa3162 |
Up-regulation | Expression | ROS1 | hsa6098 | |
In Vitro Model | PC-9 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_B260 |
PC-9/GR4 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_DH34 | |
In Vivo Model | PC-9 or PC9-GR4-AZD1 cells (4×10⁶ cells resuspended in 200 μl of 1:1 mixture of PBS / Corning Matrigel Basement Membrane Matrix) were injected subcutaneously into the right flank of mice. | |||
Result | The results suggest that DHA is able to reverse the resistance to osimertinib in EGFR-mutant NSCLC by elevating ROS level and impair heme metabolism. |
No. | Title | Href |
---|---|---|
1 | Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Pharmacol Res. 2021 Aug;170:105701. doi: 10.1016/j.phrs.2021.105701. | Click |